| Field | Specification |
|---|---|
| Target | |
| Alternative names | Vascular endothelial growth factor A;VEGF-A;Vascular permeability factor;VPF;VEGFA;VEGF; |
| UniProt # | |
| Host | |
| Clonality | |
| Isotype | |
| Reactivity | |
| Applications | |
| Immunogen | A synthetic peptide corresponding to a sequence at the N-terminus of human VEGF, identical to the related mouse and rat sequences. |
| Molecular weight | |
| Purification | |
| Reconstitution | |
| Cellular localization | |
| Concentration | |
| Form | Lyophilized |
| Storage | |
| Catalog no. (Mfr.) | |
| Main SKU |
Product Overview
This rabbit polyclonal antibody recognizes vascular endothelial growth factor A, long form (gene VEGFA) in human, mouse and rat samples and is validated for Western blot and IHC. The predicted molecular weight is 27.0 kDa, and the supplier reports an observed band at about 27 kDa.
VEGF-A is the main vascular endothelial growth factor that drives angiogenesis. Produced in response to hypoxia, it binds VEGFR1 and VEGFR2 on endothelial cells to promote their proliferation, migration and survival and to increase vascular permeability. VEGF-A is widely studied in vascular development, wound healing, eye disease and tumor angiogenesis.
| Target | Vascular endothelial growth factor A, long form (gene VEGFA; UniProt P15692, human) |
|---|---|
| Host / Clonality / Isotype | Rabbit / Polyclonal / Rabbit IgG |
| Reactivity | Human, Mouse, Rat |
| Form | Lyophilized |
| Formulation | Per vial: 0.9 mg NaCl; 0.2 mg Na2HPO4; 0.01 mg NaN3; plus stabilizers |
| Calculated MW | 27.0 kDa |
| Observed MW | 27 kDa |
| Storage | As supplied: −20 °C for up to 12 months from receipt. After reconstitution: 4 °C for up to 1 month, or aliquot and keep at −20 °C for up to 6 months. Avoid repeated freeze–thaw cycles. |
Validated Applications
| Western blot | 0.1–0.5 µg/mL (Human, Mouse, Rat) |
|---|---|
| IHC (paraffin sections) | 2–5 µg/mL (Human) |
Samples with a confirmed band (WB): Suggested blocking solution with 5% non-fat milk or BSA; (*)Recommended protein loading: 20–40 µg per lane.
Recommended loading (WB): 20–40 µg of total protein per lane.
Conditions in the example images (WB): 5–20% gradient SDS-PAGE under reducing conditions, 30 µg lysate per lane, transfer to nitrocellulose membrane, blocking in 5% non-fat milk, primary antibody at 0.5 µg/mL overnight at 4 °C, HRP-conjugated secondary antibody at 1:5000, ECL detection.
Conditions in the example images (IHC): heat-mediated antigen retrieval in EDTA buffer (pH 8.0).
Immunogen
Synthetic peptide from the N-terminal region of human VEGF. The peptide sequence is conserved in mouse and rat.
Reactivity Notes
The supplier lists reactivity with human, mouse and rat. UniProt places vascular endothelial growth factor A, long form in the [N-VEGF]: Cytoplasm and nucleus. Tissue expression noted by UniProt (human): Higher expression in pituitary tumors than the pituitary gland... The samples tested by the supplier (listed above) are a practical starting point for positive controls.
Safety
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
Hao Ling et al. (2026) Biomimetic Selenium-Encrusted Prussian Blue Nanozyme for Myocardial Infarction by Coordinated Enhancement of Mitophagy and Reactive Oxygen Species Scavenging. ACS Nano. 10.1021/acsnano.5c17071
Qiong Lu et al. (2026) CGRP Enhances the Regeneration of Bone Defects by Regulating Bone Marrow Mesenchymal Stem Cells Through Promoting ANGPTL4 Secretion by Bone Blood Vessels. Advanced Science. 10.1002/advs.202522295
Zhuxian Wang et al. (2024) Copper Ion-Inspired Dual Controllable Drug Release Hydrogels for Wound Management: Driven by Hydrogen Bonds. Small. 10.1002/smll.202401152
Zhuxian Wang et al. (2025) Ultraviolet-induced Glycyrrhiza polysaccharide hydrogels with different mechanical strength for wound management. Carbohydrate Polymers. 10.1016/j.carbpol.2025.124712
Xiaodong Hu et al. (2025) An intelligent bacterial capture nanodrug enhances immunotherapy for implant-associated infections by inducing cuproptosis-like death in bacteria. Journal of Controlled Release. 10.1016/j.jconrel.2025.114589
Xunqi Zhang et al. (2025) Precisely targeting of engineered nanovesicles to implanted scaffolds via click chemistry for microenvironment regulation in acute spinal cord injury. Journal of Controlled Release. 10.1016/j.jconrel.2025.114321
Ge Yan et al. (2024) Brucea javanica derived exosome-like nanovesicles deliver miRNAs for cancer therapy. Journal of Controlled Release. 10.1016/j.jconrel.2024.01.060
Xue Guan et al. (2025) pH-Responsive 2D Niobium Carbide Nanosheets for Targeted circPUM1 siRNA Delivery in Ovarian Cancer Therapy. Materials Today Bio. 10.1016/j.mtbio.2025.102314
Sun Zhenxing et al. (2023) Ultrasound-targeted microbubble destruction promotes PDGF-primed bone mesenchymal stem cell transplantation for myocardial protection in acute Myocardial Infarction in rats. Journal of Nanobiotechnology. 10.1186/s12951-023-02204-7
Xiangfeng Li et al. (2022) Design of macropore structure and micro-nano topography to promote the early neovascularization and osteoinductivity of biphasic calcium phosphate bioceramics. Materials & Design. 10.1016/j.matdes.2022.110581
